Clinical Trial: Renal Sympathetic Denervation From The Adventitia on Hypertension
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Efficacy and Safety of Renal Sympathetic Denervation From The Adventitia on Hypertension in Patients With Primary Aldosteronism
Brief Summary: Renal sympathetic denervation from the intima of renal arteries has become an important method for the treatment of resistant hypertension, but renal sympathetic nerve are mainly located in the adventitia, and there is no report about renal sympathetic denervation from the renal adventitia. Primary aldosteronism is an important factor of secondary hypertension, tumor aldosterone in unilateral adrenal can increase the concentration of plasma aldosterone, in some patients blood pressure control is still not desirable after resection of tumor aldosterone. This study intends to conduct renal sympathetic denervation ablation from the adventitia to observe its efficacy and safety on blood pressure of patients with primary aldosterone.
Detailed Summary:
Sponsor: Henan Institute of Cardiovascular Epidemiology
Current Primary Outcome: Change from Baseline Systolic Blood Pressure at 6 months,12 months, 18 months [ Time Frame: at 6 months,12 months,18 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Change from Baseline Renin at 6 months,12 months, 18 months [ Time Frame: at 6 months,12 months,18 months ]
- Change from Baseline aldosterone at 6 months,12 months, 18 months [ Time Frame: at 6 months,12 months,18 months ]
Original Secondary Outcome: Change from Baseline Renin and aldosterone at 6 months,12 months, 18 months [ Time Frame: at 6 months,12 months,18 months ]
Information By: Henan Institute of Cardiovascular Epidemiology
Dates:
Date Received: December 19, 2015
Date Started: December 2016
Date Completion: December 2019
Last Updated: January 9, 2017
Last Verified: January 2017
